JP2024521818A - ヘテロ環式化合物およびその使用方法 - Google Patents

ヘテロ環式化合物およびその使用方法 Download PDF

Info

Publication number
JP2024521818A
JP2024521818A JP2023573154A JP2023573154A JP2024521818A JP 2024521818 A JP2024521818 A JP 2024521818A JP 2023573154 A JP2023573154 A JP 2023573154A JP 2023573154 A JP2023573154 A JP 2023573154A JP 2024521818 A JP2024521818 A JP 2024521818A
Authority
JP
Japan
Prior art keywords
subject
associated cancer
cancer
ras
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521818A5 (https=
JPWO2022251497A5 (https=
Inventor
マルク レビンソン，アダム
ホアン，エヴリーヌ
英之 井川
ルイーズ ハースト，キム
キム，ビョンチャン
エリーアス レッフラー，アッバ
アンヘル パロメロ－バスケス，マリア
テリアン，エリック
ホアン，シエンハイ
ショーン ワッツ，カール
アルバニーズ，スティーブン
アレクサンダー ゴードン，ジェイムズ
プラチェック，アンドリュー
Original Assignee
シュレーディンガー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シュレーディンガー， インコーポレイテッド filed Critical シュレーディンガー， インコーポレイテッド
Publication of JP2024521818A publication Critical patent/JP2024521818A/ja
Publication of JP2024521818A5 publication Critical patent/JP2024521818A5/ja
Publication of JPWO2022251497A5 publication Critical patent/JPWO2022251497A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023573154A 2021-05-27 2022-05-26 ヘテロ環式化合物およびその使用方法 Pending JP2024521818A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163193831P 2021-05-27 2021-05-27
US63/193,831 2021-05-27
US202163226980P 2021-07-29 2021-07-29
US63/226,980 2021-07-29
PCT/US2022/031133 WO2022251497A1 (en) 2021-05-27 2022-05-26 Heterocyclic compounds and methods of use

Publications (3)

Publication Number Publication Date
JP2024521818A true JP2024521818A (ja) 2024-06-04
JP2024521818A5 JP2024521818A5 (https=) 2025-06-03
JPWO2022251497A5 JPWO2022251497A5 (https=) 2025-06-03

Family

ID=84229207

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573154A Pending JP2024521818A (ja) 2021-05-27 2022-05-26 ヘテロ環式化合物およびその使用方法

Country Status (5)

Country Link
US (1) US20240279221A1 (https=)
EP (1) EP4346815A4 (https=)
JP (1) JP2024521818A (https=)
KR (1) KR20240013792A (https=)
WO (1) WO2022251497A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202334095A (zh) * 2021-12-23 2023-09-01 大陸商北京望實智慧科技有限公司 Ｓｏｓ１抑制劑
EP4463454A1 (en) 2022-01-14 2024-11-20 Jazz Pharmaceuticals Ireland Limited Novel amine-substituted phthalazines and derivatives as sos1 inhibitors
CR20240362A (es) * 2022-02-04 2024-10-03 Schroedinger Inc Compuestos heterocíclicos y métodos de uso

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014169843A1 (en) * 2013-04-18 2014-10-23 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors
JP2021506864A (ja) * 2017-12-21 2021-02-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｏｓ１阻害剤としての新規なベンジルアミノ置換ピリドピリミジノンおよび誘導体
WO2023116902A1 (zh) * 2021-12-23 2023-06-29 北京望实智慧科技有限公司 Sos1抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200801996A1 (ru) * 2006-04-20 2009-04-28 Глаксо Груп Лимитед 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
ATE459358T1 (de) * 2006-12-20 2010-03-15 Glaxo Group Ltd 4-benzyl-1(2h)-phthalazinone als h1-rezeptor- antagonisten
EP3189049B1 (en) * 2014-09-05 2024-03-20 Genentech, Inc. Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer
CN118574830A (zh) * 2022-01-28 2024-08-30 中山优理生物医药有限公司 一种哒嗪并吡啶酮类化合物、其药物组合物及应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014169843A1 (en) * 2013-04-18 2014-10-23 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors
JP2021506864A (ja) * 2017-12-21 2021-02-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｏｓ１阻害剤としての新規なベンジルアミノ置換ピリドピリミジノンおよび誘導体
WO2023116902A1 (zh) * 2021-12-23 2023-06-29 北京望实智慧科技有限公司 Sos1抑制剂

Also Published As

Publication number Publication date
EP4346815A4 (en) 2025-04-02
KR20240013792A (ko) 2024-01-30
US20240279221A1 (en) 2024-08-22
WO2022251497A1 (en) 2022-12-01
EP4346815A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
JP7728367B2 (ja) がんを処置するために使用され得る尿素誘導体
JP7060694B2 (ja) Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
CA3087578C (en) Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CN102574852B (zh) Akt抑制剂
AU2018348161A1 (en) Crystalline forms
TW202523326A (zh) 雜環及其用途
JP2024521818A (ja) ヘテロ環式化合物およびその使用方法
EP4472974A2 (en) Heterocyclic compounds and methods of use
WO2022072645A2 (en) Methods for treating cancer
JP2025535066A (ja) がんを治療するための方法
WO2023173083A1 (en) Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
EP4539832A2 (en) Phenyl amide compounds and methods of use
CN117715642A (zh) 杂环化合物和使用方法
CN118974038A (zh) 杂环化合物和使用方法
EA050352B1 (ru) Гетероциклические соединения и способы использования
JP2023541047A (ja) がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤
HK40099028A (zh) 氧氮杂䓬化合物及其在癌症治疗中的用途
HK40128998A (zh) 治疗癌症的方法
CN118613480A (zh) 多环irak和flt3抑制化合物以及其用途
HK40060213A (en) 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250523

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260217